Novel therapies such as type 2 targeting biologics are emerging treatment options for
patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely …

Knowledge of chronic rhinosinusitis (CRS) epidemiology may directly impact patient care:
aiding patient identification and establishing accurate diagnosis as well as informing …

Background Dupilumab is an anti‐T2‐inflammatory biological registered for chronic
rhinosinusitis (CRS) with nasal polyps (CRSwNP), indicated by integrated CRS‐care …

Chronic rhinosinusitis (CRS) is a complex upper airway inflammatory disease with a broad
spectrum of clinical variants. As our understanding of the disease pathophysiology evolves …

Background Chronic rhinosinusitis is regarded as a chronic airway disease. According to
WHO recommendations, it may be a risk factor for COVID‐19 patients. In most CRSwNP …

Hintergrund Die chronische Rhinosinusitis (CRS) betrifft weltweit ca. 5–12% der
Allgemeinbevölkerung und wird traditionell eingeteilt in einen Phänotyp ohne (CRSsNP) …

Background Despite having a similar prevalence to Western populations, literature on
chronic rhinosinusitis (CRS) in the Asian population is sparse. There is limited data on the …

Background: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012
have had a measurable impact on the way this common condition with high impact on …

Background Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of
the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies …

Purpose Obesity is a growing, global health problem and previous cross-sectional studies
have demonstrated an association between obesity and chronic rhinosinusitis (CRS). There …